Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of mature T-cell malignancies associated with exceptionally poor prognoses. Currently, chemotherapy remains the standard of care, but outcomes are suboptimal, with 5-year survival rates ranging from 15% to 25%. In recent years, several novel agents, including pralatrexate, romidepsin, belinostat, and brentuximab vedotin, have been approved for the treatment of relapsed/refractory PTCL. In addition, numerous other therapies with different mechanisms of action and targets are currently under investigation. This article discusses in detail agents currently available, those currently under investigation, and active combination trials.
Columbia University Medical Center, Center for Lymphoid Malignancies, 51 West 51st Street, Suite 200, New York, NY 10019, USA.
Enrica
E
Marchi
Columbia University Medical Center, Center for Lymphoid Malignancies, 51 West 51st Street, Suite 200, New York, NY 10019, USA.
Alexander G
AG
Raufi
Columbia University Medical Center, Center for Lymphoid Malignancies, 51 West 51st Street, Suite 200, New York, NY 10019, USA. Electronic address: owenoconnor@columbia.edu.
Owen A
OA
O'Connor
D000630:Aminopterin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D047630:Depsipeptides / Q000627:therapeutic use; D018572:Disease-Free Survival; D006877:Hydroxamic Acids / Q000627:therapeutic use; D018796:Immunoconjugates / Q000627:therapeutic use; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000401:mortality; D013449:Sulfonamides / Q000627:therapeutic use; D015996:Survival Rate
C418863:10-propargyl-10-deazaaminopterin; D047630:Depsipeptides; D006877:Hydroxamic Acids; D018796:Immunoconjugates; D013449:Sulfonamides; D000079963:Brentuximab Vedotin; C087123:romidepsin; C487081:belinostat; D000630:Aminopterin
Antibody drug conjugates; Epigenetic; Histone deacetylase (HDAC) inhibitors; Peripheral T-cell lymphoma (PTCL); Pralatrexate